Drugs / KQ-791
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02445911 | Jun 2015 → Feb 2016 | type 2 diabetes mellitus | Kaneq Bioscience Limited | Completed | Missed primary |
| Phase 1 | NCT02370043 | Feb → Jul 2015 | — | Kaneq Bioscience Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KQ-791 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02445911 ↗ |
| Route | Oral | “Capsules administered orally while fasting, in up to 3 periods” NCT02370043 ↗ |